Health Care & Life Sciences » Pharmaceuticals | HanAll Biopharma Co. Ltd.

HanAll Biopharma Co. Ltd. | Ownership

Companies that own HanAll Biopharma Co. Ltd.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
The Vanguard Group, Inc.
859,041
1.64%
-25
0%
07/31/2018
BlackRock Fund Advisors
285,584
0.55%
0
0%
09/05/2018
Mirae Asset Global Investments Co., Ltd.
253,573
0.49%
-2,598
0.06%
04/30/2018
Norges Bank Investment Management
236,159
0.45%
1,973
0%
12/31/2017
BlackRock Advisors (UK) Ltd.
74,926
0.14%
0
0%
09/05/2018
Dimensional Fund Advisors LP
37,976
0.07%
37,976
0%
04/30/2018
Charles Schwab Investment Management, Inc.
35,709
0.07%
0
0%
09/06/2018
SSgA Funds Management, Inc.
16,546
0.03%
0
0%
09/06/2018
TIAA-CREF Investment Management LLC
15,607
0.03%
0
0%
03/31/2018
Samsung Asset Management Co., Ltd.
13,398
0.03%
-370,340
0.02%
07/06/2018

About HanAll Biopharma Co.

View Profile
Address
43 Sangseodang 1-gil
Daejeon DE 34344
Korea, Republic Of
Employees -
Website http://www.hanall.co.kr
Updated 07/08/2019
HANALL BIOPHARMA Co., Ltd. engages in the manufacture and sale of synthetic drug and biopharmaceutical. Its products include medicine for digesting, high blood pressure, cerebrovascular disease, myocardial infarction, anti-diabetics, antibiotics, gastrointestinal, bone structure, erectile dysfunction, hives and other pharmaceutical products. The company was founded by Byeong-Tae Kim on November 20, 1973 and is headquartered in Daejeon, South Korea.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.